Skip to Main content Skip to Navigation
Journal articles

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

Abstract : Infliximab is a monoclonal anti-tumor necrosis factor-α (anti-TNFα) antibody that profoundly modified the treatment of Crohn's disease (CD). The polymorphism of Fc fragment of IgG, low affinity IIIa, receptor (CD16a) [FCGR3A] influences the biological response to infliximab in patients with CD. Our aim was to study its influence on infliximab pharmacokinetics and risk of relapse after infliximab discontinuation.
Complete list of metadatas

https://hal-univ-tours.archives-ouvertes.fr/hal-02425490
Contributor : Valérie Gouilleux <>
Submitted on : Monday, December 30, 2019 - 3:53:14 PM
Last modification on : Friday, March 27, 2020 - 3:47:29 AM

Identifiers

Citation

David Ternant, Zahir Berkane, Laurence Picon, Valérie Gouilleux-Gruart, Jean-Frédéric Colombel, et al.. Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease. Clinical Pharmacokinetics, Springer Verlag, 2015, 54 (5), pp.551-562. ⟨10.1007/s40262-014-0225-3⟩. ⟨hal-02425490⟩

Share

Metrics

Record views

110